Novo Nordisk got beat out on one of the first big healthcare deals of the year — here's what the CEO is still looking for in an acquisition http://www.businessinsider.com/novo-nordisk-ceo-on-acquisition-targets-in-biotech-2018-2 The hope is to find smaller deals in the $2 billion to $3 billion range to add to the company's diabetes, hematology, or orphan disease areas rather than a mega-merger. "We continue to evaluate what's out there, and we have already some dialogues ongoing," Jorgensen said.